|

Psilocybin 25 mg Clinical Trials

2 actively recruiting trials

▼ -1 trial since May 2026

Also known as: PEX010

Pipeline

Phase 2: 2

Top Sponsors

  • Centre for Addiction and Mental Health2

Indications

  • Treatment-resistant Depression2
  • Depression2
  • Chronic Pain1

Other2 trials

Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST)
Phase 2
Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND)
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.